This is a working overview of receptor agonist, written for readers who want more than a one-paragraph summary but less than a textbook.
Reviewed 2025-08-31. Anything still debated is marked as such rather than presented as settled.
Identity and purity are usually assessed by reverse-phase high-performance liquid chromatography coupled to mass spectrometry. Retention time and observed mass are compared against a reference standard run under identical conditions. Impurity profiles reveal deamidation products, oxidized methionine variants, and truncated fragments that arise during synthesis or storage. Peptide mapping through enzymatic digestion confirms the primary sequence, while amino acid analysis offers an independent check on overall composition.
Stability studies examine how temperature, pH, and moisture influence degradation rates over time. In aqueous solution, hydrolysis and deamidation accelerate as pH moves away from mildly acidic conditions. Light exposure and residual metal ions can also trigger oxidation of susceptible residues. Accelerated aging at elevated temperature is used to estimate shelf life, though extrapolation to room temperature carries uncertainty because individual degradation pathways do not always scale predictably.
Lyophilized semaglutide powder is typically held at minus twenty degrees Celsius for long-term storage. At that temperature, solid-state degradation reactions proceed slowly and the peptide remains intact for extended periods. Repeated freeze-thaw cycles are best avoided because they promote aggregation and can shift the proportion of monomeric peptide present. Working aliquots are often prepared so that each portion is thawed only once, and desiccant is placed inside the vial to limit moisture uptake.
Solid peptide material is generally kept at reduced temperature to limit degradation. Short-term storage at 2 to 8 degrees Celsius is common, while longer archival storage at minus 20 degrees Celsius or below is typical for lyophilised powder. Vials should remain sealed and protected from light, because ultraviolet exposure can oxidise susceptible residues. Repeated freeze-thaw cycles are avoided, as they promote aggregation and loss of soluble material. Solutions are less stable than solids and are usually prepared close to the time of use.
Reversed-phase high-performance liquid chromatography is widely used to assess purity and to separate the parent peptide from related substances. Mass spectrometry confirms identity and can resolve modifications that differ by a few daltons. Size-exclusion chromatography detects dimers and higher aggregates, which are relevant to both stability and immunogenicity questions. Peptide mapping with enzymatic digestion locates specific modifications along the sequence. Circular dichroism provides a secondary-structure profile, although it gives limited information about local conformational changes.
| Property | Value | Notes |
|---|---|---|
| Appearance | White to off-white lyophilized powder | Batch-to-batch variation is normal |
| Solubility class | Soluble in water, buffer, and dimethyl sulfoxide | Aqueous solubility is moderate |
| Typical storage temperature | Minus 20 degrees Celsius dry, 2 to 8 degrees Celsius reconstituted | Avoid repeated freeze-thaw |
| Common analytical method | Reverse-phase HPLC with electrospray mass detection | Used for purity and mass confirmation |
| Common synonyms | GLP-1 analog, semaglutide peptide | Wording varies across suppliers |
Pharmacological activity arises from agonism at the glucagon-like peptide-1 receptor, a G protein-coupled receptor expressed in the pancreas, the gastrointestinal tract, and the brainstem. Receptor activation raises intracellular cyclic adenosine monophosphate and enhances insulin release in a glucose-dependent manner, an effect that diminishes when blood glucose concentration is low. Other effects include slowed gastric emptying and hypothalamic satiety signalling. These pathways are described well. Receptor desensitisation rates across tissues, relative to the endogenous hormone, are still under investigation, and reported findings differ between laboratories.
The company that developed the compound filed it as a long-acting analogue, and it gained first approval in 2017 for type 2 diabetes. Later authorisations from several regulators extended the indication to chronic weight management, and the World Health Organization added the glucagon-like peptide-1 receptor agonist drug class to its model list of essential medicines in 2023. Production uses solid-phase peptide synthesis followed by side-chain conjugation and chromatographic purification. Supply constraints and cost differences across regions are well documented. Literature on long-term outcomes continues to grow, with many trials reporting surrogate endpoints rather than hard clinical endpoints.
Semaglutide is a synthetic peptide of thirty-one amino acids that shares roughly ninety-four percent sequence identity with human glucagon-like peptide-1. Two substitutions resist enzymatic cleavage by dipeptidyl peptidase-4, and a fatty diacid side chain attached through a linker promotes binding to serum albumin. That albumin binding slows renal clearance and extends the circulating half-life from minutes to approximately one week. The structural changes are well established in the published literature. Whether the same modifications affect receptor signalling bias in ways that matter clinically remains an open question.
Semaglutide is a synthetic peptide analog of human glucagon-like peptide-1, a gut hormone released after meals. Its backbone retains the GLP-1 sequence but incorporates two substitutions that slow enzymatic breakdown by dipeptidyl peptidase-4. A short polyethylene glycol linker and a C18 fatty diacid are attached to the peptide chain, allowing the molecule to bind serum albumin and remain in circulation far longer than the native hormone. The result is a circulating half-life measured in days rather than the minutes typical of endogenous GLP-1.
Receptor activation occurs at GLP-1 receptors distributed across pancreatic islets, the hypothalamus, and the gastrointestinal tract. Binding triggers G protein signaling that raises cyclic AMP and enhances glucose-dependent insulin release. Because the effect depends on prevailing glucose levels, insulin secretion does not rise when blood sugar is already low. Signaling in the brain and gut also influences appetite and gastric emptying, which is why the compound appears in both metabolic and weight-related research literature.
Development began in the early 2010s with the goal of extending GLP-1 activity beyond the brief window achieved by native peptide infusion. The earliest approved formulation was a subcutaneous injection given once weekly. A later oral tablet pairs the peptide with an absorption enhancer, sodium N-(8-[2-hydroxybenzoyl] amino) caprylate, usually shortened to SNAC. That carrier lowers local pH and helps the peptide cross gastric tissue. Both routes deliver the same active molecule.
Activation of the GLP-1 receptor couples to Gs signalling and raises intracellular cyclic AMP in pancreatic beta cells. The resulting insulin release depends on prevailing glucose concentrations, so the effect is greater when glucose is elevated. Receptor engagement also suppresses glucagon secretion and slows gastric emptying, which flattens post-meal glucose excursions. In the central nervous system, signalling in hypothalamic and brainstem regions is associated with reduced appetite and lower energy intake. Studies continue to examine effects on cardiac, renal and hepatic endpoints; whether those benefits are independent of weight change remains an open question.
Clinical development of this compound followed earlier short-acting GLP-1 analogues that required frequent injection. Once-weekly subcutaneous formulations entered use after 2017, and an oral formulation using a permeation enhancer later became available. The oral version pairs the peptide with sodium N-(8-[2-hydroxybenzoyl] amino) caprylate, a carrier that improves uptake across the gastric epithelium. Interest has expanded from glycaemic control into weight management and metabolic liver disease. Regulatory status and approved indications differ between countries, and the product remains subject to ongoing safety monitoring.
Semaglutide is a synthetic peptide that acts as an agonist at the glucagon-like peptide-1 receptor. It is a structural analogue of human GLP-1(7-37), modified to resist enzymatic degradation by dipeptidyl peptidase-4. The peptide backbone contains alpha-aminoisobutyric acid at position 8, a substitution that stabilises the helix and slows cleavage. A fatty diacid side chain attached through a linker at lysine 34 promotes binding to serum albumin, which extends the circulating half-life. These two modifications together allow less frequent administration than native GLP-1 requires.
As a peptide, semaglutide is sensitive to conditions that break amide bonds or modify side chains. Deamidation of asparagine and glutamine residues, oxidation of methionine and tryptophan, and non-covalent aggregation are the main degradation routes described in published stability work. Rate depends strongly on pH, buffer species, ionic strength, temperature and exposure to light. Formulators therefore choose a defined solution pH and often add excipients such as phosphate buffer, propylene glycol and phenol, each of which plays a separate role in pH control, tonicity or preservation.
Storage guidance for the finished injectable product distinguishes the unused state from the in-use state. Before first use, pens are kept refrigerated between 2 and 8 degrees Celsius, protected from light, and never frozen, since freezing can disrupt the peptide or the device. After first use, label instructions in several markets permit storage at room temperature up to about 30 degrees Celsius for a limited number of days. Solid research-grade material is normally held at or below minus 20 degrees Celsius, often with desiccant, and allowed to equilibrate before opening.
Quantification and purity assessment rely on separation methods coupled to optical or mass detection. Reversed-phase high-performance liquid chromatography resolves the intact peptide from related impurities and is the standard assay technique. Size-exclusion chromatography measures aggregates, while ion-exchange chromatography separates charge variants produced by deamidation. Mass spectrometry confirms identity and detects mass shifts of a few daltons. In biological matrices, liquid chromatography with tandem mass spectrometry is often used because immunoassays can cross-react with endogenous GLP-1 or with circulating fragments.
Contemporary border control policies are complex and address a variety of distinct phenomena depending on the circumstances and political priorities of the state(s) implementing them. Consequently, several aspects of border control vary in nature and importance from region to region.
N-terminus Also amine terminus and amino terminus. The end of a linear chain of amino acids (i.e. a peptide) that is terminated by the free amine group (–NH2) of the first amino acid added to the chain during translation. This amino acid is said to be N-terminal. By convention, sequences, domains, active sites, or any other structure positioned nearer to the N-terminus of the polypeptide or the folded protein it forms relative to others are described as upstream. Contrast C-terminus.
But Edith said she had agreed to marry Field only because she felt "on the shelf" and had begun to doubt that Tolkien still cared for her. She explained that, because of Tolkien's letter, everything had changed. On 8 January 1913 Tolkien travelled by train to Cheltenham and was met on the platform by Edith. The two took a walk into the countryside, sat under a railway viaduct, and talked. By the end of the day, Edith had agreed to accept Tolkien's proposal. She wrote to Field and returned her engagement ring. Field was "dreadfully upset at first", and the Field family was "insulted and angry". Upon learning of Edith's new plans, Jessop wrote to her guardian, "I have nothing to say against Tolkien, he is a cultured gentleman, but his prospects are poor in the extreme, and when he will be in a position to marry I cannot imagine. Had he adopted a profession it would have been different." Following their engagement, Edith reluctantly announced that she was converting to Catholicism at Tolkien's insistence. Jessop, "like many others of his age and class ... strongly anti-Catholic", was infuriated, and he ordered Edith to find other lodgings. Edith Bratt and Ronald Tolkien were formally engaged at Birmingham in January 1913, and married at St Mary Immaculate Catholic Church at Warwick, on 22 March 1916. In a 1941 letter to Michael, Tolkien expressed admiration for his wife's willingness to marry a man with no job, little money, and no prospects except the likelihood of being killed in the Great War.
Sources: en.wikipedia.org
== Structure == Depending on the type of fatty acid attached to the protein, a proteolipid can often contain myristoyl, palmitoyl, or prenyl groups. These groups each serve different functions and have different preferences as to which amino acid residue they attach to. The processes are respectively named myristoylation (usually at N-terminal Gly), palmitoylation (to cysteine), and prenylation (also to cysteine). Despite the seemingly specific names, N-myristoylation and S-palmitoylation can also involve some other fatty acids, most commonly in plants and viral proteolipids. The article on lipid-anchored proteins has more information on these canonical classes. Lipidated peptides are a type of peptide amphiphile that incorporate one or more alkyl/lipid chains, attached to a peptide head group. As with peptide amphiphiles, they self-assemble depending on the hydrophilic/hydrophobic balance, as well interactions between the peptide units, which is dependent on the charge of the amino acid residues. Lipidated peptides combine the structural features of amphiphilic surfactants with the functions of bioactive peptides, and they are known to assemble into a variety of nanostructures.
lamella 1. Any thin layer, membrane, or plate of tissue, occurring in a wide variety of structures of various scales and with various functions; e.g. a lamella made of a sheet of lipids forms a component of the extracellular matrix between the cells of some tissues. 2. The leading edge of a motile cell, of which the lamellipodia is the most forward portion.
Twin helical strands form the DNA backbone. Another double helix may be found tracing the spaces, or grooves, between the strands. These voids are adjacent to the base pairs and may provide a binding site. As the strands are not symmetrically located with respect to each other, the grooves are unequally sized. The major groove is 22 ångströms (2.2 nm) wide, while the minor groove is 12 Å (1.2 nm) in width. Due to the larger width of the major groove, the edges of the bases are more accessible in the major groove than in the minor groove. As a result, proteins such as transcription factors that can bind to specific sequences in double-stranded DNA usually make contact with the sides of the bases exposed in the major groove. This situation varies in unusual conformations of DNA within the cell (see below), but the major and minor grooves are always named to reflect the differences in width that would be seen if the DNA was twisted back into the ordinary B form.
1985–1987 – 1.1 L (1,071 cc) E1, 2 barrel, 8-valve, 55 PS (40 kW; 54 hp) / 59 lb⋅ft (80 N⋅m) 1985–1987 – 1.3 L (1,296 cc) E3, 2 barrel, 8-valve, 68 PS (50 kW; 67 hp) / 71 lb⋅ft (96 N⋅m) – 60 PS (44 kW; 59 hp) in some markets, 65 PS in Switzerland 1987–1989 – 1.3 L (1,323 cc) B3, 2 barrel, 8-valve, 66 PS (49 kW; 65 hp) / 74 lb⋅ft (100 N⋅m) 1987–1989 – 1.5 L (1,498 cc) B5, 2 barrel, 12-valve, 73 PS (54 kW; 72 hp) / 81 lb⋅ft (110 N⋅m) 1985–1989 – 1.6 L (1,597 cc) B6, 8-valve, 85 PS (63 kW; 84 hp) / 90 lb⋅ft (122 N⋅m) 1985–1989 – 1.6 L (1,597 cc) B6T, turbo, 16-valve, 140 PS (103 kW; 138 hp) / 138 lb⋅ft (187 N⋅m) 1988–1991 – 2.0 L (1,998 cc) FE-SOHC, EFi, 8-valve, 118 PS (87 kW; 116 hp) / 131 lb⋅ft (178 N⋅m) (South Africa only) 1991–1994 – 2.0 L (1,998 cc) FE-DOHC, EFi, 16-valve, 146 PS (107 kW; 144 hp) / 136 lb⋅ft (184 N⋅m) (South Africa only) 1986–199? – 1.7 L (1,720 cc) PN, diesel, 8-valve, 57 PS (42 kW; 56 hp)
Sources: en.wikipedia.org
Skin and skin structure Infections This medication can be used to treat skin and skin structure infections caused from beta-lactamase-producing strains of S. aureus, Enterobacter spp., E. coli, Klebsiella spp. (including K. pneumoniae), P. mirabilis, B. fragilis, and Acinetobacter calcoaceticus. Examples of skin conditions treated with ampicillin-sulbactam are moderate to severe diabetic foot infections and type 1 Necrotizing fasciitis, commonly referred to as "flesh-eating bacteria".
===== Conjugates ===== In addition to LNPs, RNAi therapeutics have targeted delivery through siRNA conjugates (e.g., GalNAc, carbohydrates, peptides, aptamers, antibodies). Therapeutics using siRNA conjugates have been developed for rare or genetic diseases such as acute hepatic porphyria (AHP), hemophilia, primary hyperoxaluria (PH) and hereditary ATTR amyloidosis as well as other cardiometabolic diseases such as hypertension and non-alcoholic steatohepatitis (NASH).
. The complexation of a metal ion implies therefore the replacement of the coordinated water molecules with the respective ligands. The speed of this substitution plays a crucial role in the complexation kinetics and the following extraction processes. The replacement can be slow for an inert complex or rapid for a labile complex. The ligand could replace all the coordinated water molecules to form an inner sphere complex or just some of them for an outer-sphere complex. The complexation reaction is theoretically based on the Pearson's theory of hard and soft acids and bases, according to which hard acids form strong complexes with hard bases and likewise soft acids form strong complexes with soft bases. In aqueous solutions, hard-hard interactions are electrostatic, while soft-soft interactions usually show a covalent character. The formation of strong complexes always implies either a large gain of entropy or a large decrease of enthalpy thereby obtaining a large negative value of the complexation free energy. According to Pearson's theory, lanthanide and actinide ions are considered hard acids, thus they bind especially with ligands bearing hard donors such as oxygen atoms by electrostatic interactions. The charge of actinide and lanthanide ions in solution is substantially +3 and the difference in size of these cations is very small. Thus, an efficient separation of minor actinides from lanthanides is very challenging.
Sources: en.wikipedia.org
Manufacturers commonly state multi-year stability when the powder is kept dry and frozen. Actual shelf life depends on residual moisture, vial sealing, and storage temperature. A re-test by chromatography is the only way to confirm remaining purity.
Deamidated and oxidized forms are the most frequently reported impurities. Truncated peptide fragments from incomplete synthesis also appear at low levels. Their relative abundance grows with time, heat exposure, and unfavorable pH.
Retention time matching on a validated column provides strong circumstantial evidence. It does not distinguish compounds with similar hydrophobicity. Mass measurement or peptide mapping is needed for unambiguous identification.
Lower temperatures slow hydrolysis, oxidation and aggregation reactions that degrade the molecule over time. Lyophilised powder is more tolerant than solution, but both benefit from controlled conditions.